Last reviewed · How we verify

Dong-A Pharmaceutical — Portfolio Competitive Intelligence Brief

Dong-A Pharmaceutical pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
DA-5515 DA-5515 marketed Other
Placebo of DA-5515 Placebo of DA-5515 marketed

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Dong-A Pharmaceutical:

Cite this brief

Drug Landscape (2026). Dong-A Pharmaceutical — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dong-a-pharmaceutical. Accessed 2026-06-10.

Related